Life sciences company Neogen (NASDAQ: NEOG) will be reporting results this Thursday before the bell. Here’s what to expect.

Neogen beat analysts’ revenue expectations by 2.6% last quarter, reporting revenues of $209.2 million, down 3.6% year on year. It was a very strong quarter for the company, with an impressive beat of analysts’ revenue estimates and full-year revenue guidance slightly topping analysts’ expectations.

Is Neogen a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Neogen’s revenue to decline 9.3% year on year to $209.7 million, a deceleration from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $0.07 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Neogen has missed Wall Street’s revenue estimates four times over the last two years.

With Neogen being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for healthcare equipment and supplies stocks. However, there has been positive investor sentiment in the segment, with share prices up 5.3% on average over the last month. Neogen is up 27.5% during the same time and is heading into earnings with an average analyst price target of $8.17 (compared to the current share price of $7.49).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.